Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Precision BioSciences Says Baxalta's IO Focus Made It Preferred Partner

This article was originally published in Scrip

Executive Summary

Genome-editing specialist Precision BioSciences says Baxalta Inc.'s increasing commitment to, and expertise in, immuno-oncology made it the obvious choice for the Duke University spinout to partner with on developing a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed against multiple cancers.

You may also be interested in...



CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?

CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.

Meek To Drive M&A At Ipsen, Building On Two Major Launches

France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.

Ipsen Appoints Baxalta's Oncology Chief Meek CEO

Ipsen has appointed Baxalta's head of oncology David Meek as its new CEO, having formerly instigated a search in February. Baxalta's $32bn acquisition by Shire completed at the start of June.

Topics

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel